Hanmi Out-licenses pan-RAF Inhibitor to Genentech for $920 Million

South Korea's Hanmi Pharma has announced another major out-licensing: the company sold global rights (ex-Korea) for its pan-RAF inhibitor, HM95573, to Genentech, a unit of Roche, in an $910 million deal. Hanmi will receive $80 million upfront and double digit royalties on sales of certain products covered by the agreement. Further details were not provided. Hanmi has been spectacularly successful in finding partners for its portfolio of innovative drug candidates. During 2015-16, it has signed almost $7 billion of out-licensing deals. More details ..... Stock Symbols: (KRX:128940) (SIX: ROG) Share this with colleagues: // //